Breast Cancer Research and Treatment

, Volume 3, Issue 2, pp 221–224 | Cite as

Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer

  • David V. Schapira
  • Markus Schapira
Reports

Summary

Ceruloplasmin (CP), an acute phase reactant, has been found to be elevated in patients with various tumors including breast cancer. We found that the CP level was elevated in 89% of 103 patients with metastatic breast cancer. In 27 patients with measurable metastatic disease that responded to treatment the mean CP level fell by 35% (p<0.001) and in 22 patients whose disease progressed on treatment, the mean CP level rose by 44% (p<0.001). Of those patients with Stage II breast cancer that were treated with adjuvant chemotherapy, only 6% of patients with a normal post mastectomy CP level have recurred, whereas 44% of patients with an elevated post mastectomy CP level have recurred (p<0.01). In following patients with breast cancer, we noted that in those patients that recurred, the CP level became elevated 16–34 weeks prior to any clinical evidence of metastases. We also noted that the CP level became elevated after initially falling in patients receiving adjuvant chemotherapy and on occasion, the initially elevated CP level did not even fall. These circumstances may represent resistant microscopic disease, so that changing to a noncross-resistant chemotherapeutic regimen might be appropriate.

Keywords

Adjuvant therapy breast cancer ceruloplasmin recurrence prediction response to therapy tumor markers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Linder MC, Moor JR, Wright K: Ceruloplasmin assays and treatment of human lung, breast and gastrointestinal cancers. JNCI 67: 263–275, 1981PubMedGoogle Scholar
  2. 2.
    Schapira M: The presence of ceruloplasmin in cancer of the breast and female genital organs. J Roy Coll Gen Pract 22: 384–382, 1972Google Scholar
  3. 3.
    Mailer C, Swartz HM, Konieczny M, Ambegaonkar S, Moore VL: Identity of paramagnetic element found in increased concentrations in plasma of cancer patients and its relationship to other pathological processes. Cancer Res 34: 637–642, 1979Google Scholar
  4. 4.
    Hrgovcic M, Tessmer CF, Minckler TM, Mosier B, Taylor GH: Serum copper levels in lymphoma and leukemia. Cancer 21: 743–755, 1968PubMedGoogle Scholar
  5. 5.
    Raju K, Alessandri G, Gullino P: Ceruloplasmin and angiogenesis. Proc Am Assoc Cancer Res 23: 43, 1982Google Scholar
  6. 6.
    Linder MC, Moor JR: Plasma ceruloplasmin: evidence for its presence in and uptake by heart and other organs of the rat. Biochim Biophys Acta 499: 329–336, 1977PubMedGoogle Scholar
  7. 7.
    Linder MC: Serum ceruloplasmin antigen.In R Herberman (ed): Compendium of Assays for Immunodiagnosis of Cancer. Elsevier North Holland, New York, 1979, pp 311–316Google Scholar
  8. 8.
    Dionigi P, Dionigi R, Pavesi F, Mazari S, Gioggi D: Serum ceruloplasmin levels in surgical cancer patients: Relationship with tumor stage and postoperative complications. Eur Surg Res 13: 31, 1981Google Scholar
  9. 9.
    Onizuka K: Serum proteins in recurrent postoperative breast cancer. Rinsho Meneki 11: 285–293, 1979Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • David V. Schapira
    • 1
    • 2
  • Markus Schapira
    • 1
    • 2
  1. 1.Comprehensive Cancer CenterUniversity of Miami School of MedicineMiamiUSA
  2. 2.The Saskatoon Cancer ClinicUniversity HospitalSaskatoonCanada

Personalised recommendations